Stock Analysis on Net
Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

This company has been moved to the archive! The financial data has not been updated since February 15, 2024.

Common-Size Income Statement
Quarterly Data

Vertex Pharmaceuticals Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Product revenues, net 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 99.94 99.94 99.87 100.00 100.00 100.00 100.00 99.90 99.86
Other revenues 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.06 0.13 0.00 0.00 0.00 0.00 0.10 0.14
Revenues 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Cost of sales -14.62 -12.83 -12.38 -11.24 -12.30 -12.40 -11.92 -11.72 -11.94 -11.92 -12.71 -11.15 -12.48 -12.10 -12.10 -10.73 -13.09 -13.89 -14.42 -11.08
Gross profit 85.38% 87.17% 87.62% 88.76% 87.70% 87.60% 88.08% 88.28% 88.06% 88.08% 87.29% 88.85% 87.52% 87.90% 87.90% 89.27% 86.91% 86.11% 85.58% 88.92%
Research and development expenses -32.75 -32.62 -31.51 -31.27 -30.14 -27.63 -27.32 -28.66 -27.40 -23.54 -25.02 -26.35 -28.66 -32.08 -27.61 -29.60 -33.96 -58.53 -40.27 -39.55
Acquired in-process research and development expenses -0.71 -2.08 -4.43 -14.62 -0.98 -1.24 -2.82 -0.10 -6.10 -1.35 -53.44 -0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Sales, general and administrative expenses -14.66 -10.62 -10.53 -10.15 -11.61 -10.57 -9.80 -10.26 -12.31 -9.99 -10.85 -11.14 -13.01 -12.00 -12.58 -12.03 -13.82 -16.81 -16.63 -17.13
Change in fair value of contingent consideration 2.00 -0.05 0.02 0.08 -0.08 0.11 2.24 0.36 0.10 -0.06 -0.09 0.23 -0.03 -0.12 -0.60 -0.11 -0.11 -0.31 0.00 0.00
Income (loss) from operations 39.26% 41.80% 41.17% 32.80% 44.88% 48.27% 50.37% 49.63% 42.35% 53.15% -2.12% 51.49% 45.82% 43.70% 47.10% 47.54% 39.02% 10.46% 28.68% 32.25%
Interest income 7.13 6.76 5.80 5.16 3.73 1.98 0.49 0.08 0.06 0.06 0.06 0.08 0.14 0.20 0.28 0.83 0.87 1.86 1.92 1.82
Interest expense -0.42 -0.44 -0.45 -0.48 -0.50 -0.59 -0.66 -0.71 -0.73 -0.77 -0.86 -0.91 -1.00 -0.90 -0.91 -0.93 -1.01 -1.53 -1.58 -1.73
Other income (expense), net -0.39 -0.64 0.06 0.05 -1.35 0.74 -3.56 -3.47 0.34 2.14 0.45 -3.05 9.63 5.49 7.63 -4.03 9.01 -3.34 5.73 4.96
Income (loss) before (provision for) benefit from income taxes 45.58% 47.48% 46.59% 37.54% 46.76% 50.40% 46.64% 45.52% 42.02% 54.57% -2.47% 47.61% 54.59% 48.49% 54.10% 43.40% 47.90% 7.44% 34.75% 37.30%
(Provision for) benefit from income taxes -7.10 -5.79 -9.86 -8.07 -11.20 -10.53 -9.74 -9.19 -4.87 -11.63 6.20 -9.73 -17.47 -5.10 0.82 -3.62 -6.63 -1.38 -6.34 -6.00
Net income 38.48% 41.69% 36.73% 29.47% 35.56% 39.86% 36.90% 36.33% 37.16% 42.94% 3.73% 37.88% 37.12% 43.39% 54.92% 39.78% 41.27% 6.06% 28.41% 31.29%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Income (loss) from operations The net result for the period of deducting operating expenses from operating revenues. Vertex Pharmaceuticals Inc. income (loss) from operations as a percentage of revenues increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.
Income (loss) before (provision for) benefit from income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Vertex Pharmaceuticals Inc. income (loss) before (provision for) benefit from income taxes as a percentage of revenues increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.
Net income The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Vertex Pharmaceuticals Inc. net income as a percentage of revenues increased from Q2 2023 to Q3 2023 but then slightly decreased from Q3 2023 to Q4 2023 not reaching Q2 2023 level.